Mayo Clinic Q&A: FDA Sets Stricter Standards for COVID-19 Vaccine Development

  • 1 video | 18m 29s
Likes 19 Likes 19
In an effort to reassure the public about the safety and effectiveness of a vaccine, the Food and Drug Administration has set stricter standards for COVID-19 vaccine development. These standards include following phase 3 clinical trial participants for at least two months, and having at least five severe COVID-19 cases in the placebo group. The agency's requirements are designed to ensure that there is adequate safety data on any vaccine before it is authorized for emergency use. (Published 10/14/2020)


  • 18m 29s
    On the Mayo Clinic Q&A podcast, Dr. Gregory Poland, an infectious disease expert and head of Mayo Clinic's Vaccine Research Group, discusses vaccine development standards and shares concerns about the second wave of COVID-19 infections. (Published 10/14/2020) FREE ACCESS